Liver Transplant Rejection: 7 Steps to Keep Your Liver Safe

Podcast in English

Podcast in Hindi

Liver transplant rejection is a critical concern after liver transplantation (LT), where the recipient’s immune system may recognise the new liver as foreign and attempt to attack it. If not detected and treated early, rejection can lead to irreversible liver damage or graft loss.

This blog explains rejection in simple terms for patients and families while also providing detailed immunology insights for healthcare professionals.

Starzl’s Microchimerism Paradigm

• Core Concept
  • After liver transplantation, donor leukocytes migrate into the recipient’s lymphoid organs.
  • This migration results in a two-way immune conversation: donor and recipient cells recognise each other, initially clash, and then gradually undergo clonal exhaustion and peripheral deletion.
  • The outcome is microchimerism—a stable, low-level coexistence of donor leukocytes within the recipient. Microchimerism refers to the persistence of a small number of donor-derived cells (<1% of total circulating cells) in the recipient after transplantation.
  • These donor cells are multilineage and migrate to various recipient tissues, where they interact with the host immune system.
  • Microchimerism is strongly associated with long-term graft tolerance and reduced rejection episodes.

• Mechanisms of Tolerance via Microchimerism
  1. Donor-Specific Unresponsiveness
  Recipient immune cells gradually become tolerant to donor antigens.
  Analogy: Like a bridegroom who initially resists a new bride’s habits but, over time, accepts her ways as part of daily life.
  2. Regulatory T Cell Modulation
  Donor-derived cells influence recipient T-regulatory cells (Tregs), enhancing their suppressive function.
  This reduces immune activation against the graft.
  Analogy: Think of the mother-in-law (Tregs) who regulates the household. The bride (donor cells) gradually wins her over, leading to household harmony and suppression of family conflicts.
  3. Cytokine Environment and Immune Exhaustion
  Initially, transplantation triggers an inflammatory cytokine storm, much like family resistance to a newcomer.
  Over time, repeated activation leads to immune exhaustion, with diminishing capacity for rejection.
  Analogy: The extended family keeps criticising the bride at first, but eventually, they tire of complaining and adapt, leading to peace.
  

Starzl’s Key Observations

• Rejection ≠ Failure, but a Turning Point
  • Starzl suggested that the onset of rejection often coincides with the beginning of immune tolerance.
  • When treated with steroid boluses, rejection could often be reversed.
  • After reversal, the overall requirement for immunosuppression declines, since the immune system is already learning tolerance.
• Immunosuppression Strategy
  • Pre-transplant immunosuppression (if feasible) → prepares the host for tolerance.
  • Post-transplant → aim for monotherapy (single agent, usually a CNI).
  • Steroids should be reserved for rejection crises, not lifelong use.
  • High-dose or continuous immunosuppression may be harmful, as it risks destroying donor leukocytes that are essential for tolerance.
• Passenger Leukocytes
  • Around 20% of organ mass consists of donor-derived leukocytes (bone marrow origin).
  • Their migration is like giving a mini bone marrow infusion, critical for tolerance induction.
  • Over time, most disappear, leaving behind self-renewing microchimeric donor cells that help maintain acceptance.
• Experimental Findings
  • In animal models (dogs, baboons, chimpanzees), xenotransplants failed not due to T-cell rejection but because of complement activation, which cannot be controlled by tacrolimus or azathioprine.
  • This explained survival windows of 26–70 days in xenograft experiments.

Bride–Bridegroom Analogy for Microchimerism

• The Wedding (Transplant Event)
  • The bride (donor organ & leukocytes) joins the groom’s family (recipient immune system).
  • At first, both sides resist: the family doubts the bride, and the bride struggles with the family’s ways.
• Early Conflicts (Rejection)
  • Arguments break out, symbolising immune attacks.
  • But during this very conflict, both sides begin to understand that they cannot constantly fight.
• Exhaustion and Tolerance
  • Over time, both bride and family grow tired of the battles (clonal exhaustion).
  • They start accepting each other’s differences and reach a working harmony (peripheral deletion + tolerance).
• The Role of Steroids (Mediator)
  • When conflicts peak, a “mediator” (pulse steroids) may step in to calm things down.
  • Once peace is restored, the mediator withdraws, and the family continues in relative harmony without constant outside interference.
• The Balance of Presence
  • The bride must stay present in the family (donor leukocytes must persist).
  • If she disappears completely (donor cells lost), the family dominates, and the marriage collapses—symbolising graft rejection.

Starzl’s Practical Message

• Do not aim to kill donor leukocytes completely → they are the foundation of tolerance.
• Do not rely on lifelong heavy immunosuppression → it causes toxicity without aiding long-term acceptance.
• Rejection is not the end → it often marks the beginning of tolerance.
• Operational tolerance is possible → in some patients, long-term survival with minimal or no immunosuppression is achievable.

Patient-Friendly Core Sections

1. What is Liver Transplant Rejection?

Rejection occurs when the recipient’s immune system recognises donor liver cells as foreign and mounts an attack. This immune response can happen early (within weeks or months) or late (years after transplant).

2. Types of Liver Transplant Rejection Every Patient Should Know

Liver transplant rejection is classified into three main types:

1. Acute T Cell-Mediated Rejection (TCMR)
   • Timing: Typically occurs within the first 3 months.
   • Mechanism: The recipient’s T cells identify donor antigens (MHC molecules) and attack liver cells.
   • Treatment: Adjusting immunosuppressive medications; steroids may be added if needed.
   • Patient analogy: Think of T cells as soldiers. Sometimes they mistake the new liver for an enemy. Medicines act like peacekeepers, telling the soldiers to stand down.
2. Antibody-Mediated Rejection (AMR)
   • Timing: Can occur at any time after transplant, although it is rare (<1%).
   • Mechanism: Donor-specific antibodies (DSAs) bind to liver cells, triggering the complement system, causing inflammation and cell damage.
   • Treatment: Medication adjustment, sometimes plasma exchange to remove harmful antibodies.
   • Patient analogy: Antibodies are like missiles targeting the liver. Doctors can redirect or remove the missiles before they cause damage.
3. Chronic Rejection
   • Timing: Months to years after transplant.
   • Mechanism: Progressive injury leads to bile duct loss and fibrosis. Often results from repeated acute rejection episodes or a single severe AMR.
   • Treatment: Limited; retransplantation may be required in severe cases.
   • Patient analogy: Chronic rejection is like slow rusting of metal—preventive maintenance (early treatment) is essential to stop damage.

3. Warning Signs of Liver Transplant Rejection

Early detection of Liver Transplant Rejection is key. Warning signs may include:

• Jaundice: Yellowing of skin and eyes.
• Fatigue or malaise: Feeling unusually weak or tired.
• Fever or unexplained illness
• Abnormal lab tests: Elevated liver enzymes (AST, ALT) may indicate inflammation.

Patient analogy: These signs are like warning lights on your car dashboard. If ignored, bigger problems may occur. Regular follow-ups and lab tests help catch rejection early.

Professional / Advanced Section Liver Transplant Rejection

4. Diagnostic Challenges for Liver Transplant Rejection

Detecting liver transplant rejection can be tricky because the early warning signs are often subtle.

• Liver biopsy is the gold standard: Think of it like a security inspector checking every corner of your new liver. While blood tests can hint at trouble, only a biopsy can confirm if the immune system is attacking the liver. Doctors strongly discourage giving high-dose steroids without this “inspection,” because treating blindly can sometimes cause more harm.
• Clues from labs: Sometimes, elevated liver enzymes (AST, ALT) or higher eosinophil counts act like warning lights on a dashboard. They tell doctors that the immune system may be overactive, but these signs alone don’t tell the full story.
• Emerging non-invasive tests:
  • Donor cell-free DNA: Like a smoke detector in your house, it can detect early “fires” (graft injury) before obvious damage happens. However, it’s still being tested before it becomes routine.
  • Liver stiffness measurements (Fibroscan): Imagine checking if a sponge is too stiff. Fibroscan measures liver firmness, which can indicate scarring, but inflammation can make it seem falsely stiff, so the exact cause isn’t clear.
  • DSA blood tests: These measure antibodies that may attack the liver. Think of them as security cameras showing potential intruders—but they don’t always confirm if damage is actually happening.

5. T Cell-Mediated Rejection (TCMR) Explained

• TCMR occurs when recipient T cells recognise donor MHC antigens.
• Three key signals for T cell activation:
  1. Signal 1: Antigen presentation (MHC I to CD8+ T cells; MHC II to CD4+ T cells).
  2. Signal 2: Co-stimulatory molecules (CD28, CD40).
  3. Signal 3: Cytokines like IL-2 stimulate proliferation.

Professional note: Activated T cells cause hepatocyte injury, portal inflammation, and bile duct damage.

Biopsy scoring follows Banff criteria: mild (<4), moderate (4–6), severe (>7).

6. Antibody-Mediated Rejection (AMR) in Detail

• DSAs (Donor-specific antibodies) bind to HLA on endothelial cells → complement activation → microvascular injury.
• Histology: portal microvascular endothelial hypertrophy, C4d deposition, ductular reaction.

7. Chronic Liver Transplant Rejection: Mechanisms and Management

• Long-term immune injury → fibrosis, ductopenia, “vanishing bile duct syndrome.”

Immunosuppressives

• Calcineurin Inhibitors (Tacrolimus, Cyclosporine)
  • Narrow therapeutic index.
  • Side effects: nephrotoxicity, neurotoxicity, diabetes, and hypertension.
• Corticosteroids
  • Core of most protocols; tapered off in many patients.
  • Long-term use is mainly in autoimmune liver disease.
  • Risks: diabetes, hypertension.
• Mycophenolate Mofetil (MMF)
  • Inhibits lymphocyte proliferation.
  • Preferred over azathioprine (lower cancer risk).
  • Often combined with low-dose tacrolimus → renal protection.
  • Side effects: diarrhoea, bone marrow suppression, and infection.
• mTOR inhibitors (Sirolimus, Everolimus)
  • Immunosuppressive + antiproliferative effects.
  • Useful in patients with renal impairment.
  • Potential role in HCC recurrence prevention (data inconclusive).

Immunosuppressive Treatment of Allograft Rejection

• Mild T Cell-Mediated Rejection (TCMR)
  • Intensify CNI dosing.
  • Add low-dose prednisone, MMF, or mTOR inhibitors.
• Moderate–Severe TCMR
  • IV pulse steroids (methylprednisolone).
• Severe / Resistant TCMR
  • Lymphodepleting agents (ATG).
  • Risk: infections, PTLD.
• Antibody-Mediated Rejection (AMR)
  • No standardised regimen.
  • Guided by DSA levels, histology, and graft dysfunction severity.
  • First-line: Tacrolimus optimisation + steroid bolus.
  • Second-line: Plasma exchange, IVIG, Rituximab.
• Chronic Rejection
  • Minimal effective treatment options.
  • Retransplantation is definitive management.

Immune Checkpoint Inhibitors (ICIs) and Liver Transplant Rejection

ICI are used to treat cancer before or after a Liver Transplant.

• Mechanism: Block CTLA-4 / PD-1 / PD-L1 → boosts anti-tumour immunity but increases alloimmune response/disrupts immune tolerance for the graft. A minimum 3-month washout time between ICI and LT is recommended.
• Risk: Severe rejection, fatal graft injury; ICI hepatotoxicity is higher in liver allografts.
• Management:
  • Grade ≥2 hepatotoxicity → biopsy confirmation.
  • Mild: oral prednisone.
  • Moderate–severe: IV methylprednisolone.
  • Refractory: MMF, CNI reintroduction, ATG, plasmapheresis.
  • Salvage retransplantation if graft failure and no oncological contraindications.

Frequently Asked Questions

Conclusion

Liver transplant rejection reflects the delicate balance between the liver’s natural tolerance mechanisms and the recipient’s immune response. Early detection, proper medications, and vigilant monitoring are key to long-term success.

Patient takeaway: Understanding warning signs, taking medicines consistently, and maintaining healthy habits can prevent rejection and protect your new liver.
Professional takeaway: Detailed immunology knowledge helps guide therapy, monitor complications, and optimise long-term outcomes.

0

Type of Content Helps – Preference Poll

“What Type of Content Helps You Most?”

Multimedia

Podcast

FAQs ❓📚💬

Community 👥🤝🌐

Share your story

Blog 📝📰📖

Web stories

If 'Other' is filled, checked answers are ignored.